Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles American Journal of Hematology Year : 2019

Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux

Samuel Deshayes
Stéphane Cheze
  • Function : Author

Abstract

Rituximab is a second-line option in adults with immune thrombocytopenia (ITP), but the estimated 5-year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long-term safety. We conducted a prospective multicenter registry of 248 adults with ITP treated with rituximab with 5 years of
Fichier principal
Vignette du fichier
American J Hematol - 2019 - Deshayes - Long‐term safety and efficacy of rituximab in 248 adults with immune.pdf (2.22 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-04155466 , version 1 (07-07-2023)

Identifiers

Cite

Samuel Deshayes, Mehdi Khellaf, Anissa Zarour, Richard Layese, Olivier Fain, et al.. Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux. American Journal of Hematology, 2019, 94 (12), pp.1314-1324. ⟨10.1002/ajh.25632⟩. ⟨hal-04155466⟩
27 View
50 Download

Altmetric

Share

Gmail Facebook X LinkedIn More